PD-1/PD-L1抑制剂在淋巴瘤治疗中的研究进展

近年来，肿瘤生物免疫治疗因其显著的疗效而迅速发展为肿瘤研究领域的热点。程序性死亡受体-1（programmed death-1，PD-1）与其配体（programmed death ligand-1，PD-L1）在多种肿瘤细胞中过表达，参与肿瘤的发生、发展及侵袭转移。因此，PD-1/PDL1信号通路成为了肿瘤免疫治疗的有效新靶点。目前，PD-1/PD-L1抑制剂在淋巴瘤治疗研究中取得了较好的疗效。本文将对该类药物的相关临床研究现状进行综述，旨在加深对PD-1/PD-L1信号通路的作用机制及相关抗体应用于淋巴瘤治疗的认识。 

Progress of PD-1/PD-L1 inhibitors in lymphoma treatment

In recent years, tumor biological immunotherapy has rapidly become a hot topic in the field of cancer research owing to its remarkable therapeutic effects. Programmed death-1 (PD-1) and its ligand (PD-L1) are overexpressed in a variety of tumor cells and are involved in tumorigenesis, development, invasion, and metastasis. Therefore, blocking the PD-1/PD-L1 signaling pathway has become a promising new target for tumor immunotherapy. At present, PD-1/PD-L1 inhibitors have exhibited remarkable therapeutic effects in the treatment of lymphoma. This paper reviews the current status of clinical research on these drugs in order to enhance the understanding of the mechanism of PD-1/PD-L1 signaling pathway and the applications of relevant antibodies for the treatment of lymphoma.